drugset / Trial / NCT00022945

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

NCT00022945

Phase 2 Completed Corixa Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody followed by CHOP and to see what effects it has on patients with previously untreated mantel cell lymphoma.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject TOSITUMOMAB 131I Monoclonal antibody 35 mg
Subject TOSITUMOMAB 131I Monoclonal antibody 450 mg
Background Cyclophosphamide Other / unclassified
Background Doxorubicin Other / unclassified
Background Prednisone Other / unclassified
Background Vincristine Small molecule

Indications